Get started
Author

Kawther Abdilleh

Observed name: Abdilleh, Kawther
ORCID: 0009-0001-5316-9366
Observed ORCID: 0009-0001-5316-9366
OpenAlex ID: A5038472045
Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma
2024 · Abdelrahman Yousef, Mahmoud Yousef, et al. · npj Precision Oncology · 113
PDF
Blocking IL1RAP on cancer-associated fibroblasts in pancreatic ductal adenocarcinoma suppresses IL-1-induced neutrophil recruitment
2024 · Nils Hansen, Pablo Peña-Martínez, et al. · Journal for ImmunoTherapy of Cancer · 29
A cloud‐based resource for genome coordinate‐based exploration and large‐scale analysis of chromosome aberrations and gene fusions in cancer
2023 · Janet Wang, Jeanne Zheng, et al. · Genes Chromosomes and Cancer · 16
PDF
Pancreatic Cancer Action Network's SPARK: A Cloud-Based Patient Health Data and Analytics Platform for Pancreatic Cancer
2024 · Kawther Abdilleh, Omar Khalid, et al. · JCO Clinical Cancer Informatics · 7
PDF
FedECA: federated external control arms for causal inference with time-to-event data in distributed settings
2025 · Jean Ogier du Terrail, Quentin Klopfenstein, et al. · Nature Communications · 6
PDF
Understanding the Experiences of Patients With Pancreatic Cancer: Quantitative Analysis of the Pancreatic Cancer Action Network Patient Registry
2025 · Allison Rosenzweig, Sydney Rathjens, et al. · Journal of Participatory Medicine · 4
PDF
FedECA: Federated External Control Arms for Causal Inference with Time-To-Event Data in Distributed Settings
2023 · Terrail, Jean Ogier du, Klopfenstein, Quentin, et al. · arXiv (Cornell University) · 4
PDF
Germline genetic testing among patients with pancreatic adenocarcinoma: A Pancreatic Cancer Action Network patient survey
2026 · Udhayvir S. Grewal, Rishi R. Patel, et al. · Cancer · 1
Intersection of Black race and carbohydrate antigen 19‐9 nonproduction underpins worse pathologic response to neoadjuvant therapy in pancreatic cancer
2025 · Mary P. Martos, Erin M. Dickey, et al. · Cancer · 1
Association of race and CA 19-9 nonproduction with limited pathologic response to neoadjuvant chemotherapy in patients with localized pancreatic cancer.
2024 · Mary P. Martos, Erin M. Dickey, et al. · Journal of Clinical Oncology · 1
Abstract C098: Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma
2024 · Abdelrahman Yousef, Mahmoud Yousef, et al. · Cancer Research · 1
Abstract C002: Interleukin-1 receptor accessory protein (IL1RAP) overexpression is associated with worse prognosis in PDAC and is targetable by nadunolimab
2024 · Eric Van Cutsem, Kawther Abdilleh, et al. · Cancer Research · 1
Abstract A135: Optimizing the metrics: Following progress in PNET and PDAC treatments with histology, stage, and time-specific relative survival rates
2026 · Kawther Abdilleh, Kristina Harris, et al. · Cancer Research
Abstract B114: Distinct Oncogenic KRAS Mutations Shape Tumor Immunity in Pancreatic Cancer
2026 · Huanhuan Sun, Andrew Wenger, et al. · Cancer Research
MetScore and classical–basal subtype intersect to define chemotherapy response and tumor microenvironment architecture in pancreatic ductal adenocarcinoma
2026 · Raymond E. Preston, Hongyu Huang, et al. · bioRxiv (Cold Spring Harbor Laboratory)
PDF
Exploratory single‐nucleus multiomics analysis of myeloid cell states associated with neoadjuvant chemotherapy response in pancreatic ductal adenocarcinoma
2026 · Mercy Ojetunde, Li Ma, et al. · Clinical and Translational Medicine
PDF
Integrative Multi-omics Reveals Myeloid Signatures of Neoadjuvant Chemotherapy Response in Pancreatic Ductal Adenocarcinoma (PDAC) 2254994
2026 · Mercy Ojetunde, Li Ma, et al. · The Journal of Immunology
PDF
Rwd154 External Control Arm Feasibility Across External Data Sources in Oncology: Methodological and Regulatory Science Considerations
2026 · Bernat Navarro, Kawther Abdilleh, et al. · Value in Health
Erratum: Clinical Trial Participation Among Patients With Pancreatic Cancer: A Pancreatic Cancer Action Network Patient Survey
2026 · Udhayvir S. Grewal, Rishi R. Patel, et al. · JCO oncology advances.
PDF
Abstract A091: KRAS Mutation-Specific Immune Microenvironments in Pancreatic Cancer
2025 · Huanhuan Sun, Katherine Bacchi, et al. · Cancer Research
Clinical trial access in patients with pancreatic cancer (PC): A Pancreatic Cancer Action Network (PanCAN) patient survey.
2025 · Udhayvir Singh Grewal, Rishi Patel, et al. · Journal of Clinical Oncology
PDF
Germline genetic testing among patients with pancreatic cancer (PC): A Pancreatic Cancer Action Network (PanCAN) patient survey.
2025 · Udhayvir Singh Grewal, Rishi Patel, et al. · Journal of Clinical Oncology
Abstract 3654: Comparative efficacy of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: computing IPTW estimator while limiting patient data exposure with federated learning across 3 institutions
2025 · Quentin Klopfenstein, Jean Ogier du Terrail, et al. · Cancer Research
FedECA: A Federated External Control Arm Method for Causal Inference with Time-To-Event Data in Distributed Settings
2024 · Jean Ogier du Terrail, Quentin Klopfenstein, et al. · Research Square
Abstract PR012: KRAS mutation-specific effects on the tumor immune microenvironment drive tumor progression in pancreatic cancer
2024 · Andrew Wenger, Tal Baron, et al. · Cancer Research
Works count: 30
Citation count: 184
H-index: 5
I10-index: 3
Year
Topic
Type